Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer. In this multicenter, randomized, noninferiority trial, we ...

Lymphatic mapping, a recent technique first developed for the management of melanoma, is based on the concept that information about the status of the entire lymphatic drainage from a tumor site could ...

Please provide your email address to receive an email when new articles are posted on . Sentinel lymph node biopsy (SLNB) is a low-risk procedure that can reduce the need for complete lymph node ...

Please provide your email address to receive an email when new articles are posted on . Certain groups of women with early-stage breast cancer may not benefit from sentinel lymph node biopsy.

Omitting sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer undergoing breast-conserving surgery may not increase the risk for recurrence over 5 years, according to findings ...

SAN ANTONIO -- Patients with early breast cancer who skipped axillary lymph node dissection (ALND) lived just as long as those who underwent sentinel lymph node biopsy (SLNB), the randomized INSEMA ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

A randomized trial comparing axillary clearance versus no axillary clearance in older patients (≥ 60 years) with breast cancer: First results of International Breast Cancer Study Group Trial 10–93 No ...

Lymph node excision (LNEx) for patients with stage III melanoma with one clinically positive node: Excision of Lymph Node trial (EXCILYNT). Background: High-risk clinical stage II melanoma patients ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...